Pacor M L, Biasi D, Girelli D, Cortina P, Corrocher R
Istituto di Clinica Medica, Università degli Studi di Verona.
Clin Ter. 1993 Jun;142(6):529-32.
Loratadine is a new, highly selective, non sedating, H 1-receptor antagonist, without central nervous system activity. In a randomized double-blind, crossover study, we evaluated the effects of loratadine and placebo administered once daily in 184 food intolerant patients affected by urticaria-angioedema. The difference between loratadine and placebo treatment was significant in relieving symptoms. Adverse reactions reported in the treatment were mild, in fact somnolence was reported by 3.4%, dry mouth by 2.2% of patients.
氯雷他定是一种新型、高度选择性、无镇静作用的H1受体拮抗剂,无中枢神经系统活性。在一项随机双盲交叉研究中,我们评估了氯雷他定和安慰剂每日一次给药对184例患有荨麻疹性血管性水肿的食物不耐受患者的影响。氯雷他定治疗与安慰剂治疗在缓解症状方面差异显著。治疗中报告的不良反应较轻,事实上,3.4%的患者报告有嗜睡,2.2%的患者报告有口干。